Bionomics Ltd - BNOX Net earnings per share growth forecast for next year

Bionomics Limited is optimizing costs by outsourcing production and testing to third-party contractors. The expected EPS trend for the coming year reflects the current analyst consensus, with the latest value recorded as 31.70. Bionomics Limited aims to expand the BNC210 drug through B2B partnerships in neurology. The primary growth triggers will be the results of PTSD treatment trials, while current quotes already price in development expenses.

Bionomics Ltd (BNOX): Net earnings per share growth forecast for next year from 07/04/2022 to 12/24/2024

Summary analytical data breakdowns for Bionomics Limited (BNOX)

- price and consensus price forecast:

Price Chart bionomics.com.au|BNOX - Fair Value Consensus

- issuer market value details:

Market Value Bionomics|BNOX - Total Enterprise Value

- company book value details:

Net Assets per Single Share Bionomics|BNOX - Company Book Value|Market Value to Book Value Ratio bionomics.com.au|BNOX - Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

BNOX - Company Net Income|Expected Profit Bionomics Limited|BNOX - Price to Earnings Multiple|Future Price to Earnings Bionomics Ltd.|BNOX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionomics Ltd|BNOX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Bionomics|BNOX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth bionomics.com.au|BNOX - Net earnings per share growth this year|Net earnings per share growth forecast for next year Bionomics Limited

- company sales and revenue statistics:

BNOX - Company Gross Revenue|Company Future Sales Volume bionomics.com.au|BNOX - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Bionomics Ltd.

Fundamental company analysis:Bionomics, BNOX

The retention of key competencies among Australian neurologists and their regulatory potential determine the current growth forecast for Bionomics Limited (BNOX) earnings per share. This metric aggregates analyst consensus estimates for next year's EPS dynamics, measuring the expected efficiency of capitalizing on clinical successes, which allows investors to assess the probability of the company transitioning from the development stage to actual profit generation.

Key competitors